To directly address the result, we performed immunohistochemistry (IHC) of T-cell marker CD8+ and CD4+ to evaluate tumor-infiltration lymphocytes (IT-TILs) in FFPE tumor tissue, from patients received XELOX therapy or combined with anti-HER2 therapy. The gene discussed is CD8A; the disease is neoplasm.